On this page:
The use of intravesical therapy has been associated with improved survival.
Percentage of individuals receiving intravesical therapy in non-muscle invasive bladder cancer.
In 2003, 27 percent of patients with non-muscle invasive disease received intravesical therapy. New estimates will be available in 2013.
There are no Healthy People targets for cancer treatment, including bladder cancer treatment.
The use of intravesical therapy varies by geographic area, with individuals in the Midwest more likely to receive intravesical therapy compared to those living in Los Angeles. Patients of other races, primarily Asians, were more likely to receive intravesical therapy than white patients. There were no differences between white, black, and Hispanic patients in the use of intravesical therapy.
The barriers to the use of intravesical therapy should be identified.